Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML

Zhenyi Yi, Aili Chen, Lina Yan, Qiyi Chen, Hong-Hu Zhu, Qian-Fei Wang

Blood (2025) 146 (Supplement 1): 641.

https://doi.org/10.1182/blood-2025-641

Published: 2025

Journal Articles

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

Qingyu Xu, Ya-Lan Zhou, Ting Shi, Chuanying Geng, Wen Gao, Yun Leng, Yin Wu, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5646.

https://doi.org/10.1182/blood-2025-5646

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Jieyu Xu, Shihui Mao, Pumin Zhang, Hong-Hu Zhu, Jiang-Jiang Qin, Haiyan Yang

Blood (2025) 146 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2025-5093

Published: 2025

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Yebo Peng, Haixiao Zhang, Yingying Huo, Wen Gao, Ting Shi, Jianpeng Sheng, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2025-1409

Published: 2025

Journal Articles

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Yingying Huo, Haixiao Zhang, Yebo Peng, Ting Shi, Ya-Lan Zhou, Chuanying Geng, Wenjing Li, Wen Gao, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 769.

https://doi.org/10.1182/blood-2025-769

Published: 2025

Journal Articles

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

Wenjing Li, Yin WU, Chuanying Geng, Aijun Liu, Lefu Huang, Leng Yun, Yanru Zhang, Ying Tian, jing jia, Menghan Liu, Huijuan Wang, Guangzhong Yang, Hong-Hu Zhu, Wenming Chen, Wen Gao

Blood (2025) 146 (Supplement 1): 7590.

https://doi.org/10.1182/blood-2025-7590

Published: 2025

Journal Articles

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Haibo Yu, Yingying Huo, Haixiao Zhang, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 7011.

https://doi.org/10.1182/blood-2025-7011

Published: 2025

Journal Articles

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Menghan Liu, Wen Gao, Wenrong Huang, Xinan Cen, Yuan Jian, Huixing Zhou, jing jia, Wenming Chen, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2025-5766

Published: 2025

Journal Articles

Interim report of a phase 1/2 study of ESG206 in patients with refractory or relapsed primary immune thrombocytopenia

Yu Hou, Xiaolin Zhang, Hu Zhu, ziqiang Yu, Baodong Ye, Xiaoyan Xing, Qing Zhou, Ming Hou

Blood (2025) 146 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2025-3039

Published: 2025

Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood (2025) 146 (Supplement 1): 908.

https://doi.org/10.1182/blood-2025-908

Published: 2025

Journal Articles

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

Zhanrui Cheng, Shu Sun, Jiayu Wang, Bei Yang, Gejia Cao, Wen Gao, Hong-Hu Zhu

Blood (2025) 146 (Supplement 1): 6109.

https://doi.org/10.1182/blood-2025-6109

Published: 2025

Journal Articles

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Blood (2025) 146 (Supplement 1): 7546.

https://doi.org/10.1182/blood-2025-7546

Published: 2025

Journal Articles

Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration

Aili Chen, Haiyang Hu, Hong-Hu Zhu, Gang Huang, Qian-Fei Wang

Blood (2025) 146 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2025-5255

Published: 2025

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Lefu Huang, Yuechen Zhang, Huijuan Wang, Wenjing Li, Yanru Zhang, Menghan Liu, Ying Tian, Zunmin Zhu, Hong-Hu Zhu, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 7576.

https://doi.org/10.1182/blood-2025-7576

Published: 2025

Journal Articles

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong, Pengxiang Guo, Lihong Shou, Hu Zhu, Zongjiu Jiao, Feng Zhang, Qingchi Liu, Lidong Zhao, Guocai Wu, Lili Chen, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2025-5530

Published: 2025

Journal Articles

Single-Cell RNA Sequencing Uncovers Distinct Molecular Characteristics and Immune Suppression Profiling of AML with Retinoic Acid Receptor γ Rearrangement

Qing-Yu Xu, Shu Sun, Yebo Peng, Yingying Huo, Ting Shi, Wen Gao, Hong-Hu Zhu

Blood (2024) 144 (Supplement 1): 5724.

https://doi.org/10.1182/blood-2024-204959

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML

Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS)

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment

Interim report of a phase 1/2 study of ESG206 in patients with refractory or relapsed primary immune thrombocytopenia

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

High-throughput screening uncloaks actionable compounds for ttmv::rara AML

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Single-Cell RNA Sequencing Uncovers Distinct Molecular Characteristics and Immune Suppression Profiling of AML with Retinoic Acid Receptor γ Rearrangement

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only